Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 21, 2011

BAC's CaptureSelect Ligands to Be Coupled with Life Technologies' Chromatography Media and HPLC Columns

  • BAC will bring its CaptureSelect® ligands for affinity purification of antibodies to Life Technologies’ Poros® chromatography media and prepacked HPLC columns under a strategic collaboration. The suite of products is intended to provide a broad range of specificities and column formats for applications from discovery through to process monitoring.

    The collaboration will result in a variety of ready-to-use HPLC columns prepacked with CaptureSelect affinity ligands immobilized on Poros chromatography media. The selectivity of the columns is designed to support Process Analytical Technology for virtually any biopharmaceutical manufacturing process.

    BAC’s CaptureSelect products are affinity ligands and affinity resins created by a proprietary technology based on Camelid-derived single domain antibody fragments. CaptureSelect’s affinity purification and separation products are provided for the discovery, preclinical, and clinical manufacturing of therapeutic proteins including antibodies and antibody fragments.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »